Startup profile · funding coverage
BioAge Labs
Clinical-stage biotech targeting metabolic disease and aging biology (public: BIOA).
Stage
public
Status
public
Coverage
full
Why BioAge Labs is interesting
AI-driven target discovery from longitudinal health records; lead asset azelaprag in obesity trials with Lilly partnership — a16z among crossover health backers pre-IPO.
Key facts
- Series D (Feb 2024): $170M led by Sofinnova; a16z Bio + Health among existing investors (Reuters)
- IPO (Sep 2024) on Nasdaq following obesity-program partnership momentum with Eli Lilly
- Co-investors not in VCT directory: Sofinnova Investments, Longitude Capital, RA Capital, Lilly Ventures
- Source: https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-170-million-oversubscribed-series-d-financing
Investors in our directory
Funds linked from BioAge Labs's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about BioAge Labs
Funding context and why this company shows up in venture coverage.
BioAge Labs is listed among Andreessen Horowitz (a16z) investments on a16z’s public investment list.
We track a16z-backed companies that are strategically relevant for founders and investors following AI, American Dynamism, crypto, bio, and enterprise software.
Last updated: 2026-07-24